SNN

Smith & Nephew plc: Second Quarter and First Half 2026 Results Summary

Business Context and Reporting Period

This Form 6-K reports the unaudited financial results for Smith & Nephew plc for the second quarter and first half ended 27 June 2026. The company is a global medical technology business focused on Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The reporting period reflects the ongoing execution of the "RISE" strategy, which aims to accelerate growth and improve returns through portfolio expansion, innovation, and operational efficiency.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: H1 revenue grew 4.6% reported (2.3% underlying), driven by a 230bps foreign exchange tailwind. Growth was tempered by one fewer trading day compared to the prior year.
• Profitability: Trading profit increased 8.1% to $566 million, with margins expanding 60bps to 18.3%. This outperformance was driven by a step-up in efficiency savings ($130 million realized in H1) and tariff refunds that offset forecast tariff headwinds.
• Segment Performance:
  • Sports Medicine & ENT: Strong growth (10.2% reported), led by Joint Repair and Arthroscopic Enabling Technologies.
  • Advanced Wound Management: Flat underlying growth (-0.1%) due to headwinds in Bioactives (skin substitutes) following reimbursement changes, partially offset by growth in Wound Care and Devices.
  • Orthopaedics: Flat underlying growth (-0.1%) due to challenges in US Knee and Hip implants, despite growth in Trauma & Extremities.
• Cash Flow: Free cash flow decreased 5.2% to $231 million, primarily due to a $51 million increase in capital expenditure related to the new UK Wound factory and IT upgrades.

Guidance, Outlook, and Risks

• Revenue Guidance: Full-year revenue growth guidance has been reduced from "around 6%" to "around 4%". Second-half revenue growth is expected to accelerate to 5.0%–5.5% (underlying), driven by new product launches and an extra trading day in Q4.
• Profit and Cash Flow: Guidance for trading profit growth (~8% excluding acquisitions), free cash flow (~$800 million), and adjusted ROIC (>10%) remains unchanged.
• Capital Allocation: A $500 million share buyback was announced in May; $216 million was settled as of 3 August 2026. The interim dividend was increased 4.0% to 15.6 cents per share.
• Risks and Contingencies:
  • Reimbursement: Ongoing headwinds in US skin substitutes due to reimbursement rule changes, expected to impact trading profit by $20–$40 million.
  • Product Lifecycle: Temporary headwinds in US Orthopaedics (Knee and Hip) ahead of new product introductions (e.g., LANDMARK Knee System, LEGION MS).
  • Legal: Ongoing metal-on-metal hip claims, though provisions were released in the period.

Key Facts for Investor Verification

• Efficiency Savings: Verify the realization of the additional $50 million in efficiency savings identified for 2026, which is critical to maintaining profit guidance despite lower revenue growth.
• Orthopaedics Recovery: Monitor the trajectory of US Knee and Hip implant sales in H2, specifically the uptake of LEGION MS and the launch of the cementless LANDMARK system.
• Capital Expenditure: Confirm that the elevated capex in H1 (UK factory construction) does not repeat in H2, as management expects stronger cash generation in the second half.
• Acquisition Integration: Assess the integration progress of Integrity Orthopaedics (acquired Jan 2026) and its contribution to the Sports Medicine portfolio.
• Tariff Impact: Verify that the net impact of tariffs remains broadly neutral to trading profit as anticipated, relying on refunds to offset costs.